Stelios Papadopoulos highlights that hospital IRBs, which are not under FDA jurisdiction, can delay clinical trials by 6-12 months. They often second-guess FDA-approved protocols, creating a significant, decentralized, and often-overlooked hurdle for drug developers.

The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

The FDA's proposal to use non-animal models for first-in-human trials is a long-term scientific shift. However, competitors like Australia and China achieve faster trial starts now by simply streamlining existing regulatory processes, making them more attractive for biotech companies in the short-term.

The greatest barrier to biomedical advancement is the exorbitant cost ($25M+) and time (18+ months) required for the FDA's initial new drug (IND) application. By adopting a faster, notification-based system like Australia's, the U.S. could unlock a wave of innovation, lower costs, and prevent the industry from offshoring to China.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

The FDA's "Operation Trial Blazer" reforms will cut US trial launch times in half, to 15 months, but this is still seven months slower than China. The US approach focuses on making sequential processes more efficient, whereas China's model runs regulatory, ethics, and preclinical work in parallel—a higher-risk but faster strategy.

The primary bottleneck in U.S. clinical trials is not the FDA's 30-day IND approval process, but the slow, expensive 'nuts and bolts' of site activation. This includes redundant budget negotiations, contract formats, and separate scientific and IRB reviews for the same protocol across multiple institutions.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

The FDA's proposed alternative to the Investigational New Drug (IND) pathway aims to speed up Phase 1 trials by leveraging existing preclinical data. A key detail suggests this may rely on validated non-animal methods (NAMS), potentially accelerating development for some drugs but also introducing uncertainty around regulatory acceptance of these newer technologies.